Digital outcome measures in Duchenne muscular dystrophy: Lessons learnt from clinical trials
Journal of Neuromuscular Diseases · 2026-01 · 13 (1) · 77-85
DOI: 10.1177/22143602241296280 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Neuromuscular Diseases, online erschienen am 08.12.2024. Verfasst von Camila González Barral und 1 weiteren Autor:innen. Beteiligte Einrichtung: Sysnav, Vernon, France. Hauptthemen laut MEDLINE: Muscular Dystrophy, Duchenne, Clinical Trials as Topic, Outcome Assessment, Health Care. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Duchenne muscular dystrophy is a severe neuromuscular disorder characterized by progressive muscle degeneration resulting from mutations in the dystrophin gene. Digital outcome measures offer a promising alternative to traditional outcome measures used in clinical trials. This review explores the development and application of digital outcome measures in Duchenne muscular dystrophy, emphasizing the feasibility, reliability, sensitivity, and validity of these measures. The stride velocity 95th centile has been validated as a robust endpoint and has been approved for use in clinical evaluation of drugs for the treatment of Duchenne muscular dystrophy by the European Medicines Agency. Although digital outcome measures have the potential to enhance the efficiency and accuracy of clinical trials, challenges such as limited sample sizes and patient compliance persist. The integration of artificial intelligence into the data analysis is in progress, but further validation is required before these analysis strategies can be incorporated into future clinical trial methodologies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sysnav, Vernon, France.
- Neuromuscular Reference Center, Department of Pediatrics, University Hospital Liège & University of Liège, Liège, Belgium.
- MDUK Oxford Neuromuscular Centre & NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, UK.
ORCID-Profile: Camila González Barral
Zitieren
APA
González Barral, C., & Servais, L. (2026). Digital outcome measures in Duchenne muscular dystrophy: Lessons learnt from clinical trials. Journal of Neuromuscular Diseases, 13(1), 77-85. https://doi.org/10.1177/22143602241296280
Vancouver
González Barral C, Servais L. Digital outcome measures in Duchenne muscular dystrophy: Lessons learnt from clinical trials. Journal of Neuromuscular Diseases. 2026;13(1):77-85. doi:10.1177/22143602241296280
BibTeX
@article{GonzlezBarral2026,
author = {González Barral, Camila and Servais, Laurent},
title = {Digital outcome measures in Duchenne muscular dystrophy: Lessons learnt from clinical trials},
journal = {Journal of Neuromuscular Diseases},
year = {2026},
volume = {13},
number = {1},
pages = {77--85},
doi = {10.1177/22143602241296280}
}
EUVIMED